Albert Shieh1, Christina Ma2, Rene F Chun3, Jonas Wittwer-Schegg4, Leon Swinkels5, Tonnie Huijs5, Jeffrey Wang3, Ines Donangelo1, Martin Hewison6, John S Adams3. 1. Department of Medicine, University of California, Los Angeles, California. 2. David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California. 3. Department of Orthopaedic Surgery, University of California, Los Angeles, California. 4. DSM Nutritional Products, Basel, Switzerland. 5. Future Diagnostics, Wijchen, Netherlands. 6. Institute of Metabolism and Systems Research, The University of Birmingham, Birmingham, United Kingdom.
Abstract
Context: The physiologic role of free 25-hydroxyvitamin D [25(OH)D] in humans is unclear. Objective: To assess whether rise in total vs free 25(OH)D is associated with change in downstream biomarkers of 25(OH)D entry into target cells in kidney and parathyroid: 24,25-dihyroxyvitamin D [24,25(OH)2D] and PTH, respectively. Design: 16-week randomized controlled trial. Intervention: 60 μg (2400 IU)/d of D3 or 20 μg/d of 25(OH)D3. Setting: Academic medical center. Participants: 35 adults age ≥18 years with 25(OH)D levels < 20 ng/mL. Main Outcome Measures: 24,25(OH)2D, 1,25-dihyroxyvitamin D [1,25(OH)2D] and PTH. Results: At baseline, participants [D3 and 25(OH)D3 groups combined] were 35.1 ± 10.6 years. Mean total 25(OH)D, free 25(OH)D, 24,25(OH)2D, and PTH were 16.6 ng/mL, 4.6 pg/mL, 1.3 ng/mL, and 37.2 pg/mL, respectively. From 0 to 4 weeks, rise in only free 25(OH)D was associated with a concurrent 24,25(OH)2D increase [P = 0.03, adjusted for change in 1,25(OH)2D and supplementation regimen] and PTH decrease (P = 0.01, adjusted for change in calcium and supplementation regimen). Between 4 and 8 weeks, and again from 8 to 16 weeks, rises in free and total 25(OH)D were associated with 24,25(OH)2D increase; in contrast, rise in neither total nor free 25(OH)D was associated with PTH decrease during these time periods. Conclusions: Early rise in free 25(OH)D during treatment of vitamin D deficiency was more strongly associated with changes in biomarkers of 25(OH)D entry into target kidney and parathyroid cells, suggesting a physiologic role of free 25(OH)D in humans.
Context: The physiologic role of free 25-hydroxyvitamin D [25(OH)D] in humans is unclear. Objective: To assess whether rise in total vs free 25(OH)D is associated with change in downstream biomarkers of 25(OH)D entry into target cells in kidney and parathyroid: 24,25-dihyroxyvitamin D [24,25(OH)2D] and PTH, respectively. Design: 16-week randomized controlled trial. Intervention: 60 μg (2400 IU)/d of D3 or 20 μg/d of 25(OH)D3. Setting: Academic medical center. Participants: 35 adults age ≥18 years with 25(OH)D levels < 20 ng/mL. Main Outcome Measures: 24,25(OH)2D, 1,25-dihyroxyvitamin D [1,25(OH)2D] and PTH. Results: At baseline, participants [D3 and 25(OH)D3 groups combined] were 35.1 ± 10.6 years. Mean total 25(OH)D, free 25(OH)D, 24,25(OH)2D, and PTH were 16.6 ng/mL, 4.6 pg/mL, 1.3 ng/mL, and 37.2 pg/mL, respectively. From 0 to 4 weeks, rise in only free 25(OH)D was associated with a concurrent 24,25(OH)2D increase [P = 0.03, adjusted for change in 1,25(OH)2D and supplementation regimen] and PTH decrease (P = 0.01, adjusted for change in calcium and supplementation regimen). Between 4 and 8 weeks, and again from 8 to 16 weeks, rises in free and total 25(OH)D were associated with 24,25(OH)2D increase; in contrast, rise in neither total nor free 25(OH)D was associated with PTH decrease during these time periods. Conclusions: Early rise in free 25(OH)D during treatment of vitamin D deficiency was more strongly associated with changes in biomarkers of 25(OH)D entry into target kidney and parathyroid cells, suggesting a physiologic role of free 25(OH)D in humans.
Authors: John Aloia; Ruban Dhaliwal; Mageda Mikhail; Albert Shieh; Alexandra Stolberg; Louis Ragolia; Melissa Fazzari; Steven A Abrams Journal: J Clin Endocrinol Metab Date: 2015-08-27 Impact factor: 5.958
Authors: P Peris; X Filella; A Monegal; N Guañabens; L Foj; M Bonet; D Boquet; E Casado; D Cerdá; A Erra; C Gómez-Vaquero; S Martínez; N Montalá; C Pittarch; E Kanterewicz; M Sala; X Suris; J L Carrasco Journal: Osteoporos Int Date: 2017-05-02 Impact factor: 4.507
Authors: Heike Annette Bischoff-Ferrari; Bess Dawson-Hughes; Elisabeth Stöcklin; Eduard Sidelnikov; Walter Churchill Willett; John Orav Edel; Hannes Balthasar Stähelin; Swen Wolfram; Alexander Jetter; Joseph Schwager; Jana Henschkowski; Arnold von Eckardstein; Andreas Egli Journal: J Bone Miner Res Date: 2012-01 Impact factor: 6.741
Authors: S Lundgren; T Carling; G Hjälm; C Juhlin; J Rastad; U Pihlgren; L Rask; G Akerström; P Hellman Journal: J Histochem Cytochem Date: 1997-03 Impact factor: 2.479
Authors: Camille E Powe; Catherine Ricciardi; Anders H Berg; Delger Erdenesanaa; Gina Collerone; Elizabeth Ankers; Julia Wenger; S Ananth Karumanchi; Ravi Thadhani; Ishir Bhan Journal: J Bone Miner Res Date: 2011-07 Impact factor: 6.741
Authors: Ishir Bhan; Camille E Powe; Anders H Berg; Elizabeth Ankers; Julia B Wenger; S Ananth Karumanchi; Ravi I Thadhani Journal: Kidney Int Date: 2012-03-07 Impact factor: 10.612
Authors: D P Larner; C Jenkinson; R F Chun; C S J Westgate; J S Adams; M Hewison Journal: J Steroid Biochem Mol Biol Date: 2019-01-30 Impact factor: 4.292
Authors: Rene F Chun; Albert Shieh; Carter Gottlieb; Vahe Yacoubian; Jeffrey Wang; Martin Hewison; John S Adams Journal: Front Endocrinol (Lausanne) Date: 2019-10-24 Impact factor: 6.055
Authors: Fulvia Zappulo; Maria Cappuccilli; Alessandra Cingolani; Anna Scrivo; Anna Laura Croci Chiocchini; Miriam Di Nunzio; Chiara Donadei; Marianna Napoli; Francesco Tondolo; Giuseppe Cianciolo; Gaetano La Manna Journal: Int J Mol Sci Date: 2022-08-15 Impact factor: 6.208